• The big news of the day was Jazz Pharmaceuticals (JAZZ). JAZZ saw its stock catapult an astonishing 200% ahead of the SLEEP 2009 (Associated Professional Sleep Societies) conference. JAZZ is scheduled to present data from its clinical trial of sodium oxybate in patients with fibromyalgia. [BizJournals]

• Icahn on board – Amylin and Biogen for sale? [WSJ health Blog]

• FDA adds fainting warning for Gardasil. [WSJ]

• FTC such a pain in the butt — first CSL/Talecris and now 12-14 years too long exclusivity period for biosimilars. [Reuters]

• Cell Therapeutics’ (CTIC) Bianco and Co. gets some nice payouts for stayin’ alive. [Xconomy]

• Stevie Cohen bets on Vanda Pharmaceuticals (VNDA). [BusinessWire]

• AstraZeneca (AZN) gets a break in Seroquel scandal. [WSJ health Blog]

• Metabasis Therapeutics’ (MBRX) $6M deal with Merck (MRK) may not be enough to keep the company afloat. [Yahoo!Finance]

• SEC suing banker over GSK deal. [Bloomberg]

• Adam Feuerstein at The Street says investor rejected Rodman’s plea to raise cash for struggling Hemispherx Biopharma (HEB). [The Street]

• Finally, the FDA has cleared the use of antipsychotic drugs for children and teens, despite the lack of long-term safety data. [Bloomberg]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts